Release
Date ![[down]](http://us.i1.yimg.com/us.yimg.com/i/fi/down.gif) |
Contributor |
Author |
Title |
Pages |
Price |
StarMine Author Rating | More Info |
| EPS Accuracy * |
Portfolio Return ** |
| 1-Feb-10 | Brean Murray & Co., Inc. | Jonathan M. Aschoff PhD | KERX: Keryx Reports Positive Phase 2 Results in Waldenstrom’s Macroglobulinemia | 4 | $10 |  | | View Abstract | | 1-Feb-10 | Brean Murray & Co., Inc. | Eric M. Beder, Jonathan M. Aschoff PhD, Michael Gaugler, Daniel Fidell, Ling Wang CFA, Ananda Baruah | Morning Insight (ARW, AVT, ACI, ADLR, KERX, AEO, ANF, ARO, URBN, WTSLA, GES, JCG, NST, Utility Weekly Review, Clean Energy Weekly Review, Water Works Weekly) | 15 | $50 | | | View Abstract | | 29-Jan-10 | Brean Murray & Co., Inc. | Eric M. Beder, Jonathan M. Aschoff PhD, Ling Wang CFA, Bret Jones, Ananda Baruah, Jeremy Sussman | Morning Insight (CNX, IMGN, CPSI, QSII, EK, AVT, FLWS) | 9 | $25 | | | View Abstract | | 27-Jan-10 | Brean Murray & Co., Inc. | Jonathan M. Aschoff PhD | RDEA: Positive Update after Meeting with Management | 5 | $10 | | | View Abstract | | 27-Jan-10 | Brean Murray & Co., Inc. | Eric M. Beder, Jonathan M. Aschoff PhD, Ryan Worst CFA, Daniel Fidell, Bret Jones, Ye (Ingrid) Yin Ph.D. | Morning Insight (BTU, CBPO, RDEA, ATHN, CERN, CPSI, ECLP, EM, MDRX, PFWD, QSII, WMS, BEBE, GES, NWY) | 9 | $25 | | | View Abstract | | 25-Jan-10 | Brean Murray & Co., Inc. | Jonathan M. Aschoff PhD | KERX: Reports Positive Updated Perifosine Data in Refractory Colorectal Cancer | 5 | $10 | | | View Abstract | | 25-Jan-10 | Brean Murray & Co., Inc. | Jonathan M. Aschoff PhD | PARD: Poniard Reports Positive Final Phase 2 Results in Colorectal Cancer | 6 | $25 | | | View Abstract | | 25-Jan-10 | Brean Murray & Co., Inc. | Eric M. Beder, Jonathan M. Aschoff PhD, Michael Gaugler, Daniel Fidell, Ling Wang CFA, Ananda Baruah | Morning Insight (IM, ANF, HBI, FLWS, GAME, SNDA, KERX, PARD, SBS, Water Works Weekly, Clean Energy Weekly Review, Utility Weekly Review) | 16 | $50 | | | View Abstract | | 19-Jan-10 | Brean Murray & Co., Inc. | Jonathan M. Aschoff PhD, Jose Haresco, Ling Wang CFA, Bret Jones | Health Care: Top Picks for 2010 (ALGN, ALXN, AMMD, ATHN, CERN, CPSI, ECLP, HNSN, IMGN, MDRX, MDVN, OMPI, QSII, UTHR) | 14 | $50 | | | View Abstract | | 19-Jan-10 | Brean Murray & Co., Inc. | Jonathan M. Aschoff PhD | NKTR: Recent Data Reduces Risk in Pegylating Small Molecule Drugs – Raising Target Price | 4 | $10 | | | View Abstract | | 19-Jan-10 | Brean Murray & Co., Inc. | Eric M. Beder, Jonathan M. Aschoff PhD, Ryan Worst CFA, Michael Gaugler, Daniel Fidell, Jose Haresco, Ling Wang CFA, Bret Jones, Jeremy Sussman | Morning Insight (NKTR, PERY, WRC, Health Care Top Picks for 2010, Coal Earnings Preview, Gaming Earnings Preview, Retail Pricing Study, Clean Energy Weekly Review, Utility Weekly Review, Water Works Weekly) | 18 | $50 | | | View Abstract | | 12-Jan-10 | Brean Murray & Co., Inc. | Jonathan M. Aschoff PhD | NKTR: Nektar Therapeutics (Nektar Announces Impressive Preliminary Results from NKTR-102 Phase 2 Trial in Platinum-Resistant Ovarian Cancer Patients | 4 | $10 | | | View Abstract | | 11-Jan-10 | Brean Murray & Co., Inc. | Eric M. Beder, Jonathan M. Aschoff PhD, Michael Gaugler, Daniel Fidell, Bret Jones | Morning Insight (RICK, FOSL, HBI, MDRX, RDEA, Water Works Weekly, Clean Energy Weekly, Utilities Weekly) | 14 | $50 | | | View Abstract | | 7-Jan-10 | Brean Murray & Co., Inc. | Jonathan M. Aschoff PhD | RDEA: Ardea Annouces Positive Results from Phase 2a and Phase 1 Drug-Drug Interaction Trials | 4 | $10 | | | View Abstract | | 5-Jan-10 | Brean Murray & Co., Inc. | Jonathan M. Aschoff PhD | BIIB: Terminating Coverage of Biogen Idec | 4 | $10 | | | View Abstract | | 5-Jan-10 | Brean Murray & Co., Inc. | Jonathan M. Aschoff PhD | KERX: Keryx Receives Zerenex SPA – Has Sufficient Capital to Conduct Phase 3 Trials for Both Zerenex and Perifosine | 4 | $10 | | | View Abstract |
|